tecentriq concentrate for solution for infusion
f. hoffmann-la roche ltd. 4303 kaiseraugst-secondary packager - atezolizumab - concentrate for solution for infusion - 60mg/ml
lartruvo
eli lilly nederland b.v. - olaratumab - sarcoma - antineoplastic agents - lartruvo is indicated in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin (see section 5.1).
cyramza 500mg50ml concentrate for solution for infusion vials
eli lilly and company ltd - ramucirumab - solution for infusion - 10mg/1ml
cyramza 100mg10ml concentrate for solution for infusion vials
eli lilly and company ltd - ramucirumab - solution for infusion - 10mg/1ml
blincyto 38.5micrograms powder for concentrate and solution for solution for infusion vials
amgen ltd - blinatumomab - powder for solution for infusion - 38.5microgram
empliciti 400mg powder for concentrate for solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - elotuzumab - powder for solution for infusion - 400mg
empliciti 300mg powder for concentrate for solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - elotuzumab - powder for solution for infusion - 300mg
darzalex 100mg5ml concentrate for solution for infusion vials
janssen-cilag ltd - daratumumab - solution for infusion - 20mg/1ml
darzalex 400mg20ml concentrate for solution for infusion vials
janssen-cilag ltd - daratumumab - solution for infusion - 20mg/1ml
lartruvo 500mg50ml concentrate for solution for infusion vials
eli lilly and company ltd - olaratumab - solution for infusion - 10mg/1ml